TECH · BIO-TECHNE Corp
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Nov 30, 2022; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $431.98M | Year Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP EBITDA 343.44M
+9.96M Amortization of Wilson Wolf intangible assets
+8.57M Acquisition related expenses and other
+5.51M Certain litigation charges
+42.64M Stock-based compensation, inclusive of employer taxes
+21.06M Restructuring and restructuring-related costs
+5.01M Investment loss and other non-operating loss
-6.79M Impairment (Recovery) of assets held-for-sale
+2.57M Impact of business held-for-sale
= Adjusted EBITDA 431.98M
|
|||
| Adjusted gross margin percentage non-GAAP | 69.6% | Full Year FY2026 | — |
|
|
|||
| Adjusted operating income non-GAAP | $386.1M | Full Year FY2026 | — |
|
|
|||
| Adjusted operating margin percentage non-GAAP | 31.9% | Year Ended June 30, 2026 | — |
|
|
|||
| Diagnostics and Spatial Biology segment operating income | $37.7M | Year Ended June 30, 2026 | — |
| Diagnostics and Spatial Biology segment operating margin | 11.2% | Full Year FY2026 | — |
|
|
|||
| Diagnostics and Spatial Biology segment revenue | $336.37M | Year Ended June 30, 2026 | — |
| Protein Sciences segment operating income | $359.4M | Year Ended June 30, 2026 | — |
| Protein Sciences segment operating margin | 41.1% | Full Year FY2026 | — |
|
|
|||
| Protein Sciences segment revenue | $874.62M | Year Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TECH
this stock
BIO-TECHNE Corp
|
$11.31B | +23.2% | +5.2% | 104.7 | 5.9% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +21.5% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +16.5% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +5.0% | +20.8% | 20.3 | 3.3% |
|
ARGX
Argenx SE
|
$61.75B | +22.8% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Nov 30, 2022; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TECH | +0.4% | +1.0% | +25.1% | +0.5% | +23.2% |
| SPY | -0.4% | +2.6% | +10.7% | +2.7% | +12.5% |
| vs SPY | +0.8% | -1.6% | +14.4% | -2.2% | +10.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.